Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability.

Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, Schimel DM, Cochard AE, Wang X, Schechter AN, Noguchi CT, Gladwin MT.

Blood. 2007 Apr 1;109(7):3088-98. Erratum in: Blood. 2008 Feb 15;111(4):1772.

2.

Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice.

Kaul DK, Liu XD, Chang HY, Nagel RL, Fabry ME.

J Clin Invest. 2004 Oct;114(8):1136-45.

3.

Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress.

Kaul DK, Zhang X, Dasgupta T, Fabry ME.

Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H39-47. doi: 10.1152/ajpheart.00162.2008. Epub 2008 May 2.

4.

Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease.

Nath KA, Shah V, Haggard JJ, Croatt AJ, Smith LA, Hebbel RP, Katusic ZS.

Am J Physiol Regul Integr Comp Physiol. 2000 Dec;279(6):R1949-55.

5.

Sickle cell anemia and vascular dysfunction: the nitric oxide connection.

Akinsheye I, Klings ES.

J Cell Physiol. 2010 Sep;224(3):620-5. doi: 10.1002/jcp.22195. Review.

PMID:
20578237
6.

Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.

Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM Jr, Gladwin MT.

JAMA. 2005 Jul 6;294(1):81-90.

7.

Hypoxia-induced acute lung injury in murine models of sickle cell disease.

Pritchard KA Jr, Ou J, Ou Z, Shi Y, Franciosi JP, Signorino P, Kaul S, Ackland-Berglund C, Witte K, Holzhauer S, Mohandas N, Guice KS, Oldham KT, Hillery CA.

Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L705-14. Epub 2003 Sep 12.

8.

Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.

Kato GJ, Gladwin MT.

JAMA. 2008 Dec 10;300(22):2638-46. doi: 10.1001/jama.2008.598. Review.

9.

Arginase Inhibition Reverses Endothelial Dysfunction, Pulmonary Hypertension, and Vascular Stiffness in Transgenic Sickle Cell Mice.

Steppan J, Tran HT, Bead VR, Oh YJ, Sikka G, Bivalacqua TJ, Burnett AL, Berkowitz DE, Santhanam L.

Anesth Analg. 2016 Sep;123(3):652-8. doi: 10.1213/ANE.0000000000001378.

10.

Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse.

Kaul DK, Liu XD, Fabry ME, Nagel RL.

Am J Physiol Heart Circ Physiol. 2000 Jun;278(6):H1799-806.

11.

Sickle cell disease vasculopathy: a state of nitric oxide resistance.

Wood KC, Hsu LL, Gladwin MT.

Free Radic Biol Med. 2008 Apr 15;44(8):1506-28. doi: 10.1016/j.freeradbiomed.2008.01.008. Epub 2008 Jan 26. Review.

PMID:
18261470
12.

Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin.

Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ.

Blood. 2007 Sep 15;110(6):2166-72. Epub 2007 May 29.

13.

Low micromolar intravascular cell-free hemoglobin concentration affects vascular NO bioavailability in sickle cell disease: a computational analysis.

Deonikar P, Kavdia M.

J Appl Physiol (1985). 2012 Apr;112(8):1383-92. doi: 10.1152/japplphysiol.01173.2011. Epub 2012 Jan 5.

14.

Vasculopathy and pulmonary hypertension in sickle cell disease.

Potoka KP, Gladwin MT.

Am J Physiol Lung Cell Mol Physiol. 2015 Feb 15;308(4):L314-24. doi: 10.1152/ajplung.00252.2014. Epub 2014 Nov 14. Review.

15.

Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Kato GJ, Gladwin MT, Steinberg MH.

Blood Rev. 2007 Jan;21(1):37-47. Epub 2006 Nov 7. Review.

16.

Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.

Gladwin MT, Kato GJ.

Hematology Am Soc Hematol Educ Program. 2005:51-7.

17.

Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT.

Blood. 2006 Mar 15;107(6):2279-85. Epub 2005 Nov 15.

18.

Priapism in sickle-cell disease: a hematologist's perspective.

Kato GJ.

J Sex Med. 2012 Jan;9(1):70-8. doi: 10.1111/j.1743-6109.2011.02287.x. Epub 2011 May 6. Review.

19.

A novel hemoglobin-binding peptide reduces cell-free hemoglobin in murine hemolytic anemia.

Hanson MS, Xu H, Flewelen TC, Holzhauer SL, Retherford D, Jones DW, Frei AC, Pritchard KA Jr, Hillery CA, Hogg N, Wandersee NJ.

Am J Physiol Heart Circ Physiol. 2013 Jan 15;304(2):H328-36. doi: 10.1152/ajpheart.00500.2012. Epub 2012 Nov 2.

20.

Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

Morris CR, Morris SM Jr, Hagar W, Van Warmerdam J, Claster S, Kepka-Lenhart D, Machado L, Kuypers FA, Vichinsky EP.

Am J Respir Crit Care Med. 2003 Jul 1;168(1):63-9. Epub 2003 Mar 5.

PMID:
12626350

Supplemental Content

Support Center